Novo Nordisk Faces Wegovy Patent Challenge While Betting on AI and Oral Therapies
Published on 09/29/2026 at 03:01 | Editorial boerse-global.de
Novo Nordisk's flagship obesity drug is under legal fire in the United States, just as the Danish pharmaceutical group accelerates a multi-front effort to diversify its pipeline and modernize its research operations.
Mylan Pharmaceuticals, a subsidiary of drugmaker Viatris, filed suit Friday in a U.S. federal court in Delaware, seeking a judicial declaration that a planned generic version of Wegovy does not infringe Novo Nordisk's existing patents. Reuters reported the filing. The outcome carries significant stakes for the Danish company: Wegovy ranks among its primary revenue drivers and has powered its global growth in recent years. Should copycat manufacturers breach the patent barriers in the U.S. market ahead of schedule, pricing pressure on Novo's products would intensify considerably.
AI Partnership and Brand Overhaul
On the research side, Novo Nordisk is embedding artificial intelligence into its laboratory workflows to speed up drug discovery. The company signed a collaboration with AI specialist Anthropic on September 16, according to Reuters, centering on the use of Anthropic's Claude models in research and development. The algorithms are intended to help scientists identify promising molecules and make data analysis in early development stages more efficient.
The move accompanies a broader organizational repositioning. On September 14, the group announced it will operate under the shortened brand name Novo in day-to-day use, while the legal name Novo Nordisk A/S remains unchanged. An internal culture initiative called "The Novo Way" underpins the shift.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Pipeline Deals and Oral Focus
Beyond internal digitalization, Novo is leaning on partnerships to widen its drug portfolio. A licensing and development alliance with Orbis Medicines, announced September 17, carries a potential total value of up to $1.4 billion and focuses on researching oral therapies for cardiometabolic diseases. Novo is also taking a strategic stake in Orbis as part of the transaction.
Such agreements reflect management's response to fierce competition in the metabolic therapies market. Alongside conventional injections, tablet-based formulations are moving increasingly into the strategic spotlight for pharmaceutical manufacturers. CEO Mike Doustdar told Reuters that oral weight-loss pills could capture as much as half of the global obesity drug market by 2030. He also urged the company's workforce to sharpen its customer focus in order to regain lost ground in the obesity segment.
NYSE Listing Under Consideration
To bolster its position in the world's most important pharmaceutical market on the capital markets side as well, the group is weighing changes to its listing structure. Doustdar told the Financial Times that Novo Nordisk is examining a direct listing on the New York Stock Exchange as a replacement for its currently traded ADR certificates.
Meanwhile, the company continues its social initiatives. Under a program with UNICEF to prevent childhood obesity, Novo Nordisk pledged an additional $18 million for the period from 2026 to 2030, aiming to reach more than 80 million children worldwide.
Market Performance
The initiatives fit into the broader strategy management has laid out for the coming years, with the company aiming to consistently broaden its pipeline and significantly expand global patient care over the current decade. Investors, however, have remained cautious. The stock closed yesterday at EUR 34.05, down 23% since the start of the year and 38% below its 52-week high. In more recent trading, the shares stood at EUR 34.15, a modest gain of 0.3%, with the year-to-date decline at 22%.
Ad
Novo Nordisk Stock: New Analysis - 29 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
